These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 38174864)

  • 21. Description of a large cohort of Caucasian patients with V122I ATTRv amyloidosis: Neurological and cardiological features.
    Gentile L; Di Bella G; Minutoli F; Cucinotta F; Obici L; Mussinelli R; Arimatea I; Russo M; Toscano A; Vita G; Mazzeo A
    J Peripher Nerv Syst; 2020 Sep; 25(3):273-278. PubMed ID: 32395865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis.
    Louwsma J; Brunger AF; Bijzet J; Kroesen BJ; Roeloffzen WWH; Bischof A; Kuhle J; Drost G; Lange F; Kuks JBM; Gans ROB; Hazenberg BPC; Nienhuis HLA
    Amyloid; 2021 Mar; 28(1):50-55. PubMed ID: 32883119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7.
    Dyck PJB; González-Duarte A; Obici L; Polydefkis M; Wiesman JF; Antonino I; Litchy WJ; Dyck PJ
    J Neurol Sci; 2019 Oct; 405():116424. PubMed ID: 31445300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hereditary transthyretin amyloidosis in middle-aged and elderly patients with idiopathic polyneuropathy: a nationwide prospective study.
    Fargeot G; Echaniz-Laguna A; Labeyrie C; Svahn J; Camdessanché JP; Cintas P; Chanson JB; Esselin F; Piedvache C; Verstuyft C; Genestet S; Lagrange E; Magy L; Péréon Y; Sacconi S; Signate A; Nadaj-Pakleza A; Taithe F; Viala K; Tard C; Poinsignon V; Cauquil C; Attarian S; Adams D
    Amyloid; 2024 Mar; 31(1):62-69. PubMed ID: 37855400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hereditary transthyretin amyloidosis overview.
    Manganelli F; Fabrizi GM; Luigetti M; Mandich P; Mazzeo A; Pareyson D
    Neurol Sci; 2022 Dec; 43(Suppl 2):595-604. PubMed ID: 33188616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
    Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
    Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
    Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A compound score to screen patients with hereditary transthyretin amyloidosis.
    Tozza S; Severi D; Spina E; Di Paolantonio A; Iovino A; Guglielmino V; Aruta F; Nolano M; Sabatelli M; Santoro L; Luigetti M; Manganelli F
    J Neurol; 2022 Aug; 269(8):4281-4287. PubMed ID: 35279758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
    Coelho T; Marques W; Dasgupta NR; Chao CC; Parman Y; França MC; Guo YC; Wixner J; Ro LS; Calandra CR; Kowacs PA; Berk JL; Obici L; Barroso FA; Weiler M; Conceição I; Jung SW; Buchele G; Brambatti M; Chen J; Hughes SG; Schneider E; Viney NJ; Masri A; Gertz MR; Ando Y; Gillmore JD; Khella S; Dyck PJB; Waddington Cruz M;
    JAMA; 2023 Oct; 330(15):1448-1458. PubMed ID: 37768671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Olatunji G; Kokori E; Abraham IC; Omoworare O; Olatunji D; Ezeano C; Emmanuel Adeoba B; Stanley AC; Oluwatobiloba AM; Oluwademilade OB; Shimelis KM; Olanisa O; Aderinto N
    Medicine (Baltimore); 2024 Jun; 103(26):e38767. PubMed ID: 38941378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry.
    Parker MM; Damrauer SM; Tcheandjieu C; Erbe D; Aldinc E; Hawkins PN; Gillmore JD; Hull LE; Lynch JA; Joseph J; Ticau S; Flynn-Carroll AO; Deaton AM; Ward LD; Assimes TL; Tsao PS; Chang KM; Rader DJ; Fitzgerald K; Vaishnaw AK; Hinkle G; Nioi P
    Sci Rep; 2021 Jun; 11(1):11645. PubMed ID: 34079032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis.
    Lin X; Yarlas A; Vera-Llonch M; Baranwal N; Biber J; Brown D; Vogt B; Karam C
    BMC Neurol; 2021 Feb; 21(1):70. PubMed ID: 33579211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hereditary transthyretin-mediated amyloidosis with polyneuropathy: baseline anthropometric, demographic and disease characteristics of patients from a reference center.
    Sequeira VCC; Penetra MA; Duarte L; Azevedo FR; Sayegh RSR; Pedrosa RC; Cruz MW
    Arq Neuropsiquiatr; 2022 Mar; 80(3):262-269. PubMed ID: 34755769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
    Lyng CS; Gude E; Hodt A; Knudsen EC
    Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hereditary Transthyretin Amyloidosis and the Impact of Classic and New Treatments on Kidney Function: A Review.
    Meléndrez-Balcázar E; Aranda-Vela K; Cervantes-Hernández A; López-Cureño S
    Am J Kidney Dis; 2024 Aug; 84(2):224-231. PubMed ID: 38484868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK.
    Gillmore JD; Reilly MM; Coats CJ; Cooper R; Cox H; Coyne MRE; Green AJ; McGowan R; Moody WE; Hawkins PN
    Adv Ther; 2022 Jun; 39(6):2292-2301. PubMed ID: 35419651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Neurological manifestations of ATTR amyloidosis].
    Pernice HF; Hahn K
    Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
    Adams D; Tournev IL; Taylor MS; Coelho T; Planté-Bordeneuve V; Berk JL; González-Duarte A; Gillmore JD; Low SC; Sekijima Y; Obici L; Chen C; Badri P; Arum SM; Vest J; Polydefkis M;
    Amyloid; 2023 Mar; 30(1):1-9. PubMed ID: 35875890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management Targeted Genetic Evaluation of an Idiopathic Neuropathy Cohort Through ATTRv Amyloidosis Screening.
    Fisher KA; Diaz S; Gelblum J; Brock C; Suresh N; Towne M
    HCA Healthc J Med; 2024; 5(4):405-413. PubMed ID: 39290488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
    Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
    J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.